Literature DB >> 8541224

SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens.

W Hua1, T Christianson, C Rougeot, H Rochefort, G M Clinton.   

Abstract

Estrogen receptor positive ovarian cancer is often refractile to antiestrogen therapy. Here we describe the SKOV3 human ovarian carcinoma cell line as an in vitro model for estrogen and antiestrogen resistant ovarian cancer. While SKOV3 cells expressed estrogen receptor (ER) mRNA and protein at a similar level as the estrogen responsive T47D breast carcinoma cell line, their growth was not responsive to estradiol (E2) and was not inhibited by the antiestrogens OH-tamoxifen and ICI 164,384. The ER in SKOV3 cells was normal with respect to apparent Kd for binding with E2, E2 regulation of a transiently transfected ERE driven reporter gene, and E2 stimulation of expression of the early growth response genes c-myc and c-fos. However, the SKOV3 cells exhibited no expression of the progesterone receptor gene (PR) even after addition of E2, and the protein products of the estrogen responsive genes HER-2/neu and cathepsin D were expressed at constitutive levels that were not regulated by E2. Therefore, estrogen resistance in these cells may be a result of constitutive expression and loss of E2 regulation of selected growth regulatory gene products rather than a defect in estrogen activation of ER as a transcriptional regulator.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541224     DOI: 10.1016/0960-0760(95)00187-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  23 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis.

Authors:  Ahmad Ghasemi; Jafar Saeidi; Mahnaz Mohtashami; Seyed Isaac Hashemy
Journal:  Mol Cell Biochem       Date:  2019-05-10       Impact factor: 3.396

3.  Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

Authors:  Rajendra P Tanpure; Amanda R Harkrider; Tracy E Strecker; Ernest Hamel; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2009-08-12       Impact factor: 3.641

4.  Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.

Authors:  Bradley R Corr; Jessica Finlay-Schultz; Rachel B Rosen; Lubna Qamar; Miriam D Post; Kian Behbakht; Monique A Spillman; Carol A Sartorius
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

5.  Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

Review 6.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

7.  Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.

Authors:  William J Murdoch; Edward A Van Kirk; Dale D Isaak; Youqing Shen
Journal:  Gynecol Oncol       Date:  2008-05-20       Impact factor: 5.482

8.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Authors:  K M Lau; S C Mok; S M Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells.

Authors:  G M Clinton; C Rougeot; J Derancourt; P Roger; A Defrenne; S Godyna; W S Argraves; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.

Authors:  Imen Kallel; Maha Rebai; Abdelmajid Khabir; Nadir R Farid; Ahmed Rebaï
Journal:  J Biomed Biotechnol       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.